Dr. Ningbo Liu 刘宁波
Chief Physician
Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiation therapy and comprehensive treatment for thoracic tumors, particularly lung cancer, esophageal cancer, and thymoma.
Dr. Liu is Chief of the Radiobiology Laboratory and a doctoral supervisor at Tianjin Medical University Cancer Institute & Hospital. Trained under Academician Yu Jinming, Dr. Liu conducted preclinical translational research on lung cancer for one year in 2012 at the US National Cancer Institute. The doctor has published over 100 papers, including more than 20 SCI-indexed articles as first or corresponding author.
Professional roles
- Vice Chair, Youth Committee of Radiation Oncology Professional Committee, China Anti-Cancer Association
- Deputy Leader, Radiobiology Group, Radiation Oncology Branch, Chinese Medical Doctor Association
- Standing Committee Member, Tumor Particle Therapy Professional Committee, China Anti-Cancer Association
- Secretary-General, Lung Cancer Study Group, Radiation Oncology Professional Committee, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Liu Ningbo). Papers usually list the name as Ningbo Liu or Liu N.
Selected publications
44 papers on PubMed matched by name and affiliation; 12 as first or senior author since 2016. Most recent first- or senior-author papers:
- Transl Lung Cancer Res, 2026 (senior author): Consolidation thoracic radiotherapy following quadruple induction with benmelstobart, anlotinib, and chemotherapy for extensive-stage small cell lung cancer: rationale and protocol of a phase II study. PubMed 42433250
- Radiat Oncol, 2026 (senior author): Preliminary results from a phase II trial of spatially fractionated radiotherapy combined with immunotherapy and anti-angiogenic therapy in patients with bulky solid tumors: early evidence of promising efficacy and favorable safety. PubMed 42063096
- Transl Lung Cancer Res, 2025 (senior author): Radiomics-clinical integration guides prophylactic cranial irradiation decisions in limited-stage small cell lung cancer: a brain metastasis risk stratification model. PubMed 40799424
- Front Immunol, 2025 (senior author): Low dose radiotherapy combined with immune checkpoint inhibitors induces ferroptosis in lung cancer via the Nrf2/HO-1/GPX4 axis. PubMed 40539046
- Discov Oncol, 2025 (senior author): Simultaneous integrated dose reduction intensity-modulated radiotherapy improves survival in patients with locally advanced non-small cell lung cancer by reducing cardiac irradiation exposure. PubMed 40069527
- BMC Cancer, 2024 (senior author): Effectiveness of CT radiomic features combined with clinical factors in predicting prognosis in patients with limited-stage small cell lung cancer. PubMed 38310283
- Cancer Biol Med, 2023 (senior author): Simultaneous integrated dose reduction intensity-modulated radiotherapy effectively reduces cardiac toxicity in limited-stage small cell lung cancer. PubMed 37300284
- Front Oncol, 2022 (senior author): Practice Patterns of Treatment Strategy of Limited-Stage Small-Cell Lung Cancer: Survey of Chinese Oncologists. PubMed 35651806
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion